Respiratory Medicine - Thoracic Oncology Cluster, Ghent University Hospital, Ghent, Belgium.
Respiratory Medicine - Tumor Immunology Laboratory, Ghent University, Ghent, Belgium.
Front Immunol. 2021 Feb 12;11:620374. doi: 10.3389/fimmu.2020.620374. eCollection 2020.
Lung cancer remains the leading cause of cancer-related death worldwide. The advent of immune checkpoint inhibitors has led to a paradigm shift in the treatment of metastatic non-small cell and small cell lung cancer. However, despite prolonged overall survival, only a minority of the patients derive clinical benefit from these treatments suggesting that the full anti-tumoral potential of the immune system is not being harnessed yet. One way to overcome this problem is to combine immune checkpoint blockade with different strategies aimed at inducing or restoring cellular immunity in a tumor-specific, robust, and durable way. Owing to their unique capacity to initiate and regulate T cell responses, dendritic cells have been extensively explored as tools for immunotherapy in many tumors, including lung cancer. In this review, we provide an update on the nearly twenty years of experience with dendritic cell-based immunotherapy in lung cancer. We summarize the main results from the early phase trials and give an overview of the future perspectives within this field.
肺癌仍然是全球癌症相关死亡的主要原因。免疫检查点抑制剂的出现导致转移性非小细胞肺癌和小细胞肺癌的治疗发生了范式转变。然而，尽管总生存期延长，但只有少数患者从这些治疗中获得临床获益，这表明免疫系统的全部抗肿瘤潜力尚未得到充分利用。克服这个问题的一种方法是将免疫检查点阻断与不同的策略相结合，旨在以肿瘤特异性、强大和持久的方式诱导或恢复细胞免疫。由于树突状细胞具有独特的启动和调节 T 细胞反应的能力，因此它们已被广泛探索作为许多肿瘤（包括肺癌）免疫治疗的工具。在这篇综述中，我们提供了近 20 年来肺癌树突状细胞免疫治疗经验的最新进展。我们总结了早期临床试验的主要结果，并概述了该领域的未来展望。
